← Browse by Condition
Medical Condition

thyroid carcinoma anaplastic

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for thyroid carcinoma anaplastic sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — thyroid carcinoma anaplastic Clinical Trials

How many clinical trials are currently recruiting for thyroid carcinoma anaplastic?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for thyroid carcinoma anaplastic, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for thyroid carcinoma anaplastic?
thyroid carcinoma anaplastic research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a thyroid carcinoma anaplastic clinical trial?
Eligibility criteria for thyroid carcinoma anaplastic trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
Cancer Research UK 1 trial

Recruiting Clinical Trials

NCT07440290 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
View Trial →

Related Conditions

haematological malignancy (1) malignant neoplasm (1) lymphoproliferative disorders (1) neoplasms by histologic type (1) neoplasms by site (1) gastrointestinal cancer (1) non melanoma skin cancer nmsc (1) langerhans cell histiocytosis lch (1) cancer (1) erdheim chester disease (1) thyroid carcinoma papillary (1) ovarian neoplasms (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology